Trial Profile
A Multicenter, Double-Blind, Randomized, Placebo and Active-Controlled, Parallel Study to Evaluate the Lipid Altering Efficacy and Safety of MK0767 in Patients With Metabolic Syndrome and Dyslipidemia
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 09 May 2022
Price :
$35
*
At a glance
- Drugs MK 0767 (Primary) ; Fenofibrate
- Indications Hyperlipidaemia
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 02 Mar 2014 New trial record